For the past three years, we have studied the genetics of schizophrenia with colleagues from South Africa. We undertook this project-specifically in the South African Xhosa population-not because the Xhosa have a particularly high incidence of schizophrenia (they do not), but because we were interested in cross-cultural perceptions of schizophrenia, in gene-environment interaction in a very different geographic setting, and in the transfer of genomics technology to African labs. All these features of the project were, and remain, fascinating. But there is a dimension to the project that we only now fully appreciate: the unique contribution of African populations to the genetics of complex traits.
Africa is the most informative place on earth to discover the genetic bases of complex human traits because Africa harbors more human genetic variation than anywhere else. The impact of this fact on gene discovery is only now being fully realized, but the observation itself is not new. The richness of human genetic variation in Africa has been documented for decades, for example, by the elegant illustration that heterozygosity genomewide is highest in East Africa and decreases worldwide with distance from that point (Li et al., 2008) (Figure 1) .
The reason for the richness of human genetic variation in Africa is also not a mystery: people have lived in Africa longer than anywhere else. Humans and chimpanzees diverged in Africa 5-6 million years ago. Ancient hominins evolved in Africa over the next 5 million years, with appearance of modern humans approximately 200,000 years ago and migrations out of Africa of small groups of modern humans beginning approximately 100,000 years ago (Nielsen et al., 2017) (Figure 2) . In other words, about 99% of our evolutionary experience as a species was spent in Africa.
This timeline has direct consequences for profiles of genetic variation in modern human populations. At one extreme, common polymorphisms found in all human populations date to the early evolution of our species, and indeed, many common polymorphisms are shared with chimpanzees. The SNPs of the HapMap vary in frequencies from place to place, but essentially all are polymorphic everywhere. At the other extreme, in recent Because only small groups of humans left Africa, most of the lessthan-ubiquitous variation that existed 100,000 years ago remained on the African continent. That is, among rare alleles, those that left Africa were a small sample of the whole.
The genetics of African populations reveals this ''missing layer'' of human variation; that is, variation that arose between 100,000 and 5 million years ago. The only place to study this variation is in Africa. To the extent that human genetics research includes only out-of-Africa populations, thousands of generations of human evolution are lost.
Modern African populations are enriched for alleles that likely originated between 100,000 and 5 million years ago ( Figure 3 ). Frequencies of these alleles are generally a few percent, far more rare than worldwide SNPs, yet more common than very recent and private variants found in all populations. Despite this enriched diversity, African populations have no greater burden of deleterious variants than do non-African populations (Do et al., 2015; Lohmueller, 2014) . If anything, the mutational load for mildly deleterious alleles increases with increasing distance from sub-Saharan Africa as a result of less efficient purifying selection due to successive migration bottlenecks (Henn et al., 2016) . Thus, African populations may be enriched for alleles that confer phenotypic variation in traits that, throughout evolution, have had neutral or positive impact on reproductive fitness. In modern, longer-lived populations, some of these alleles may influence illnesses with onset later in life.
For example, the identification of genetic variants associated with extreme LDL and HDL cholesterol levels relied disproportionately on alleles of African origin. The discovery of individually rare alleles associated with low HDL cholesterol and a higher risk of coronary disease (Cohen et al., 2004) , as well as the discovery of individually rare alleles associated with lower LDL cholesterol and, therefore, protection against coronary disease (Cohen et al., 2006) , each depended to a great extent on the presence of these alleles in individuals of African ancestry.
Some alleles that are critical to modern disease have persisted in African populations as the result of gene-environment interactions that are long-lasting over time but localized geographically. For example, end-stage kidney disorders are more common among persons of African ancestry than among persons of European or Asian ancestry. The reason is genetic: susceptibility to the two major forms of severe kidney disease, focal segmental glomerulosclerosis and hypertension-attributed end-stage kidney disease, is significantly increased-with odds ratios of 10.5 and 7.3-by two common mutations in apolipoprotein L1 (APOL1). These mutations are specific to certain African populations and persist because they protect against sleeping sickness (Genovese et al., 2010) . These mutant APOL1 proteins, but not wildtype APOL1 protein, lyse Trypanosoma brucei rhodesiense, a major cause of African trypanosomiasis. Hence, these variants have been under long-term positive selection in regions of subSaharan Africa where trypanosomiasis was endemic, but they lead to severe disorders of post-reproductive onset among the same African populations in diaspora. The relationship of kidney disease, trypanosomiasis, and APOL1 is an evolutionary example of gene-environment interaction involving one gene and two severe common diseases.
The richness of genetic variation in African populations also offers the opportunity to explore innovative models of complex inheritance. For example, private or de novo mutations of severe effect on neuropsychiatric disorders often vary in expressivity and penetrance. One integrative hypothesis is an oligogenic model, whereby two or more damaging alleles may contribute to severe neurodevelopmental illnesses (Turner et al., 2017) . In patients and properly selected controls from the same African populations, it is possible to test for simultaneous enrichment of both private/de novo mutations and of ancient functional alleles under the hypothesis that the latter may individually have escaped negative selection but confer susceptibility when coupled with more recent alleles of severe effect. These effects could appear as digenic or oligogenic inheritance involving two or more genes. These effects are not limited to African populations, certainly, but are more likely to be detected in these populations because they offer the opportunity to screen more genetic variation with far greater time depth. Furthermore, these models can be tested in case-control studies of reasonable size because effects of interest have non-trivial odds ratios, are biologically meaningful, and can be functionally evaluated.
The value of gene discovery in any population rests on the simple but fundamental truth that biological pathways that are critical to human development are universal. A gene harboring mutations that influence a human trait in anyone, anywhere, is part of the normal biology underlying that trait in everyone, everywhere. A gene discovery based on a family of any ancestry is informative for other families worldwide with mutations in the same gene.
African populations of healthy individuals provide another independent insight for gene discovery. African populations provide a human-species-wide backdrop for gauging mutation tolerability in any gene identified as a candidate for any phenotype in any population-African or otherwise. With advanced sequencing technologies, the challenge for gene discovery is not finding mutations; the challenge is determining which mutations matter. Because populations of African ancestry harbor far more variation than do populations of other ancestries, the tolerated mutational burden of any human gene can be most fully assessed in African controls. This contribution has been clear in the ExAC and gnomAD databases (Lek et al., 2016) and will be substantially greater as more African populations are sequenced. We suggest that every casecontrol study for genetics of common disease, in any population, include both population-matched controls and data from African controls. African controls capture far more variation than other controls in virtually every gene, representing rare variation tolerated after 100-fold longer exposure to evolutionary pressures.
Finally, it is important that candidate risk alleles that are identified in any population be evaluated in populations of diverse ancestry before concluding that the alleles are causal. Failure to adequately assess candidate disease alleles across populations can lead to false positive results with potentially disastrous clinical consequences. For example, five common variants, previously classified as causal for hypertrophic cardiomyopathy, are much more common in people of African ancestry (Manrai et al., 2016) . The association studies implicating these variants apparently included a small proportion of patients of African ancestry without appropriate controls. Since the frequency of each allele is several-fold higher in African populations than in non-African populations, the initial positive associations were due to population stratification, not to disease risk. The failure to adequately control for population diversity resulted in benign variants being characterized as pathogenic on clinical genetics tests and patients being misinformed as to their genetic risk for serious heart disease.
In summary, human genomic diversity and its relationship to common complex human traits can only be fully understood in the context of human evolution. The genomic diversity of African populations provides a unique opportunity to detect and characterize genes that matter for important human traits worldwide. To return to our original theme, investigators who are particularly well qualified to work with patients with such traits-understanding cultural context, historical demography, and gene/environment interactions-are scientists from the same places as the patients they are studying. Productive science and capacity building are fully complementary and tightly linked. Building infrastructure in the context of active scientific research offers enormous promise for gene discovery (H3Africa Consortium et al., 2014) .
